Skip to main content
Figure 5 | BMC Pharmacology

Figure 5

From: Rapamycin weekly maintenance dosing and the potential efficacy of combination sorafenib plus rapamycin but not atorvastatin or doxycycline in tuberous sclerosis preclinical models

Figure 5

Sorafenib, atorvastatin and doxycycline do not affect whole blood rapamycin levels in nude mice bearing Tsc2-/- tumors. (a) Tumor rapamycin levels from rapamycin treated group (n = 5) and sorafenib plus rapamycin combination treated group (n = 4). (b) Whole blood rapamycin levels from rapamycin treated group (n = 8), atorvastatin plus rapamycin combination treated group (n = 8) and doxycycline plus rapamycin combination treated group (n = 8). Rapamycin levels were measured 24 hours after the last dose of rapamycin for all groups.

Back to article page

BMC Pharmacology

ISSN: 1471-2210